In March 2005, Lynx Therapeutics merged with UK firm Solexa. The firm will now do business under the new name. In November of 2006 Solexa was subsiquintly acquired by SBIR firm Illumina, Inc of California, Lynx Therapeutics (Nasdaq:LYNXD) is a developer of application of novel genomics analysis solutions for the discovery of gene sequence and expression information important to the pharmaceutical, biotechnology, and agricultural industries. These solutions are based on Megaclone⢠and MPSSâ¢, the company's proprietary cloning and sequencing technologies. Lynx is developing DNA cloning and analysis technologies designed to enhance gene discovery, gene expression, genome mapping, characterization of gene functions, and the study of plant and animal genes. Possible applications include identifying the cause of diseases through genetic variations; studying and manipulating important crops such as wheat, corn, and rice; and targeting drug therapies. Its proprietary technologies for rapidly identifying massive numbers of genes and mapping DNA sequences are untested in the marketpla
